Ironwood (IRWD) Better-Than-Expects Q4 Results; On Track for FDA Submission of NDA for Linaclotide
Tweet Send to a Friend
Ironwood Pharmaceuticals (NASDAQ: IRWD) reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
